LifeSci Capital analyst Sam Slutsky has maintained their bullish stance on PYXS stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sam Slutsky’s rating is based on Pyxis Oncology’s promising developments in their pipeline, particularly with their drug candidate MICVO, which targets solid tumors. The company has shown an efficacy signal in head and neck squamous cell carcinoma (HNSCC) patients, which stands out among other tumor types. This positive data has led Pyxis to plan further development of MICVO in HNSCC and other solid tumors, including breast cancer, with ongoing dose-escalation studies.
Additionally, Pyxis Oncology’s strategic collaboration with Merck for a clinical trial involving Keytruda enhances the potential for successful outcomes. The company’s financial position, with over a year of cash runway, supports its ongoing research and development efforts. These factors contribute to Sam Slutsky’s optimistic outlook and Buy rating for Pyxis Oncology’s stock.
According to TipRanks, Slutsky is a 4-star analyst with an average return of 10.9% and a 40.05% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Abivax SA Sponsored ADR, Celldex, and DBV Technologies SA – American.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $5.00 price target.